China Hospital Drug Buying Slows, Biologics Outpace Market In 2013: McKinsey & CPA
This article was originally published in PharmAsia News
Executive Summary
Drug sales monitored at select hospitals in China rose at a double digit rate in 2013, but that is still a slower pace than recent years as the impact of a compliance storm hit. Biologics however gained faster than small molecules and show potential for even greater growth, according to a recent report from global consulting firm McKinsey & Co and the CPA.
You may also be interested in...
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.